Background: Carbapenem-resistant Enterobacteriaceae (CRE) represent an urgent threat because few drugs are available to treat infections caused by these pathogens. Plazomicin is a novel aminoglycoside that recently completed a Phase 3 clinical trial for treatment of infections caused by CRE.
Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) represent one of the most urgent antibiotic resistance threats as defined by the US CDC. 1 These MDR pathogens are unresponsive to multiple antibiotics, and are responsible for increased morbidity and mortality in infected patients. 2 In the USA the most common cause of CRE is the production of KPC carbapenemases, which usually appear in the same organism with other broad-spectrum b-lactamases. 3 Thus, these organisms are resistant to almost all b-lactam antibiotics used as monotherapy, as well as to currently approved aminoglycosides and fluoroquinolones, whose resistance determinants are frequently carried on the same plasmid as a b-lactamase gene. 3 Plazomicin, formerly ACHN-490, 4 is a new aminoglycoside that is being developed with the intention to treat serious bacterial infections such as complicated urinary tract infections and acute pyelonephritis, bloodstream infections, and hospital-acquired and ventilator-associated pneumonia caused by CRE. 5 Like other aminoglycosides, it inhibits bacterial protein synthesis and exhibits dose-dependent bactericidal activity. 4, 6 Plazomicin, with stability to inactivation by most aminoglycoside-modifying enzymes (AMEs), has antibacterial activity against many Grampositive and Gram-negative bacteria, particularly Gram-negative bacteria that harbour plasmid-encoded AMEs. 4 As a result, plazomicin has demonstrated activity against many CRE strains with plasmids that encode both carbapenemases and AMEs. 7 Our laboratory has been monitoring the epidemiology of CRE from central Indiana healthcare centres since 2009, and has identified isolates that produce mainly KPC serine carbapenemases together with common penicillinases; co-production of MBLs occurred in 8 of the 174 isolates. 8 For this study, we selected 110 representative CRE isolates with varied phenotypes and tested them against plazomicin and appropriate comparator agents. 
Materials and methods

Antibacterial agents
With the exception of plazomicin, which was furnished by Achaogen, all antibacterial agents were obtained from the US Pharmacopeial Convention (USP, Rockville, MD, USA).
Bacterial strains
CRE isolates from discrete patients originating from 2010-13 were provided by two clinical microbiology laboratories that service 14 healthcare centres and two large urban hospitals in central Indiana, USA. 8, 9 The central laboratories conducted initial testing using a Vitek 2 automated system, with carbapenemase activity identified based on the Modified Hodge Test (MHT), as recommended by CLSI at the time the isolates were collected. 10 All isolates with a positive MHT result were later tested for carbapenemase activity using the Carba NP test with imipenem as the substrate. 11 All confirmed CRE isolates from one central laboratory (n " 172) and two SME-producing Serratia marcescens isolates from a second laboratory during this time period were examined. Based on bacterial species, differences in susceptibility profiles and b-lactamase production, 110 isolates were selected as representative of the full collection.
b-Lactamase characterization
For the carbapenemase-producing isolates, bla genes were identified using PCR. Plasmid DNA from all isolates and genomic DNA from S. marcescens were purified with the GenElute TM Bacterial Genomic DNA Kit (Sigma Life Science). Genomic DNA was screened for the presence of bla SME 12 and plasmid DNA was screened for the presence of bla CTX-M , bla OXA , bla SHV , bla TEM , bla KPC , bla IMP , bla NDM and bla VIM by PCR amplification with published primer sets. 8, 13 PCR products that were positive for bla genes were sequenced using the BigDye 3.1 kit (Applied Biosystems) and analysed by BLAST.
In vitro susceptibility test methods
MICs for all agents were determined by broth microdilution according to CLSI guidelines, 14 using Escherichia coli ATCC 25922 as the quality control. The most recent CLSI interpretive criteria were applied. 15 Duplicate assays were conducted on separate days, with additional replicates assayed if MIC values were non-identical for the first pair of results. The median MIC was reported for non-duplicative results.
WGS
WGS was performed on the Klebsiella pneumoniae isolate KP-88 with a plazomicin MIC of 256 mg/L. Bacterial DNA was prepared as above. Individual libraries of prokaryotic genomic material were PCR amplified using the NEXTflex Rapid DNA-Seq Kit (Bioo Scientific Corporation, Austin, TX, USA), pooled and submitted for sequencing with an Illumina NextSeq500 using a NextSeq 500/550 Mid Output v2 kit (150 cycles) (Illumina, San Diego, CA, USA). Bioinformatics performed on the data included microbial genome assembly and prokaryotic genome annotation. Reads were mapped to reference genomes (GenBank files from NCBI) using breseq (v0.27.1). 16 
Results
The bacterial isolates and their putative b-lactamase families are listed in Table 1 . All isolates contained a serine carbapenemase; three S. marcescens isolates produced the Serratia-specific SME-1 enzyme, while all others produced either a KPC-2 or KPC-3 carbapenemase. Eight isolates co-produced MBLs together with a KPC carbapenemase: one bla NDM-1 gene was identified and seven bla VIM genes were detected, identical to or closely related to bla VIM-1 , in isolates determined to be non-clonal by PFGE (A. Tulpule, Indiana University, personal communication). Consistent with the proportion seen in the full collection, K. pneumoniae isolates represented 87% of the isolates tested.
Susceptibility profiles and MIC distributions, as shown in Table 2 , demonstrate that plazomicin was the most potent of all the agents tested, with MIC 50 and MIC 90 values of 0.5 and 1 mg/L, respectively, against all the isolates. The mean and modal MICs for plazomicin were both 0.5 mg/L, with only four MICs .2 mg/L. When the subset of 96 KPC-producing K. pneumoniae isolates was analysed, MIC 50 and MIC 90 values were both 0.5 mg/L (data not shown). Gentamicin was the next most active of the agents, demonstrating 81.8% susceptibility. Amikacin was the only other aminoglycoside to demonstrate .10% susceptibility: 23.6% of all the isolates were susceptible; 68% of the isolates had MICs in the intermediate range. Full resistance to amikacin and gentamicin (MICs exceeding 64 and 16 mg/L, respectively) was observed in 9 and 17 isolates, respectively. The isolates in the collection were highly resistant to kanamycin and tobramycin, especially for the KPCproducing K. pneumoniae, which were 98% non-susceptible. Plazomicin against CRE JAC Likewise, as expected, the isolates were also highly resistant to the carbapenems, imipenem and meropenem. None of the isolates was susceptible to imipenem, although three isolates (2.7%), two K. pneumoniae and one Enterobacter cloacae, did demonstrate susceptibility to meropenem. The SME-1/SHV-producing S. marcescens isolate with a plazomicin MIC of 8 mg/L was susceptible to amikacin, gentamicin and kanamycin with MICs of 16, 4 and 16 mg/L, respectively. The K. pneumoniae isolate, KP-88 with a plazomicin MIC of 256 mg/L, produced both a KPC-3 serine carbapenemase and the MBL NDM-1, and was highly resistant to all of the aminoglycosides (MICs 32 mg/L). Based on WGS, this strain encoded the AME AAC(6 0 )-Ib and the ArmA 16S rRNA methyltransferase; 17 the latter enzyme was not identified in any of the other isolates in the collection.
Discussion
Among these contemporary carbapenem-resistant isolates from the central USA, KPC-producing pathogens were prevalent. These CRE isolates generally responded to plazomicin with MICs lower than those observed for most other antibiotics tested, similar to data reported in previous studies with carbapenem-resistant enteric bacteria from diverse geographic regions. 4, 6, 7, 18 Across all the studies reported in the literature, plazomicin MICs were 4 mg/L, except for a set of CRE isolates producing the NDM-1 MBL. 18 These data correlate well with our results, whereby we showed that plazomicin MICs were 4 mg/L, except for one K. pneumoniae and one S. marcescens isolate ( Table 2) . The latter isolate, with a plazomicin MIC of 8 mg/L, was susceptible to amikacin, gentamicin and kanamycin, and produced both the SME serine carbapenemase and the SHV-12 ESBL. The only isolate that was highly resistant to plazomicin was KP-88, a K. pneumoniae strain that produced KPC-3 and NDM-1, a stable combination of serine and metallocarbapenemases that confers resistance to all b-lactam antibiotics and b-lactamase inhibitor combinations including the recently approved ceftazidime/avibactam combination. 19 Based on WGS, this strain encoded the AME AAC(6 0 )-Ib and the ArmA 16S rRNA methyltransferase known to affect aminoglycoside susceptibility. 18 According to earlier work, AAC(6 0 )-Ib does not confer resistance to plazomicin. 4, 6 However, in previous studies of NDMproducing CRE isolates, Livermore et al. 18 showed that the bla NDM-1 gene was co-transferred with armA or rmtC methylase genes associated with resistance to other aminoglycosides as well as to plazomicin. Thus, the presence of the ArmA methyltransferase in the NDM-1-producing KP-88 isolate explains the observed elevated MICs for plazomicin and the other aminoglycosides included in this study.
Based on the data presented in this study, plazomicin was the most potent antibacterial agent tested against a panel of highly resistant CRE isolates from the central part of the USA. Because both carbapenem and associated co-resistance mechanisms can vary based on geography, it is critical to understand potential differences in plazomicin activity based on the geographic origin of CRE isolates. These results suggest that plazomicin may have a role in the future in the treatment of infections caused by these pathogens. Zhang et al.
